APVO:NSD-Aptevo Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 32.51

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

0.07M

Average Target Price

USD 55.00 (+69.18%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Company Website : http://aptevotherapeutics.com

Address : 2401 4th Avenue, Seattle, WA, United States, 98121

Employees : 80

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 7.46

52 Week High : 60.00

Short Ratio : 1.44

52 Week Low : 2.94

Shorted Shares : 152,967

200 Day Moving Average : 18.94

Shorted Shares Previous Month : 165,747

50 Day Moving Average : 39.57

Shares Held By Insiders : 59.25%

Short Percentage : 3.00%

Shares Held by Institutions : 75.18000000000001%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD55.27B 18.98 14.09
MRNA Moderna, Inc

N/A

 USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD34.27B 36.37 33.83
SGEN Seagen Inc

N/A

 USD33.25B 70.15 66.51
RPRX Royalty Pharma plc

N/A

 USD32.48B 22.60 11.76
BGNE BeiGene, Ltd

N/A

 USD31.24B N/A N/A
GMAB Genmab A/S

N/A

 USD28.71B 26.59 3.08
BNTX BioNTech SE

N/A

 USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing APVO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.30% 4% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.30% 4% F 3% F
Trailing 12 Months  
Capital Gain 4,680.88% 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4,680.88% 100% A+ 100% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 436.93% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 436.93% 98% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,387.09% 1% F 1% F
Risk Adjusted Return 31.50% 62% D- 56% F
Market Capitalization 0.14B 28% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 40.80 23% F 28% F
Price/Book Ratio 72.72 2% F 2% F
Price / Cash Flow Ratio -3.36 28% F 66% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -316.98% 7% F 2% F
Return on Invested Capital -104.67% 24% F 9% F
Return on Assets -38.59% 28% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.44 66% D 66% D
Short Percent 3.71% 70% C- 47% F
Beta 7.46 0% N/A 0% N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector